5-HT1A receptor ligands and their therapeutic applications: review of new patents.
INTRODUCTION
5-HT1AR was one of the first discovered serotonin receptors and is one of the most thoroughly studied. Dysfunctions associated with 5-HT1AR neurotransmission are linked to several psychiatric disorders, including anxiety, depression, and movement disorders.


AREAS COVERED
The current review covers patent literature published between January 2012 and May 2018. Queries were performed on Espacenet, SciFinder, clinicaltrials.gov, pharmacodia.com, and the websites of pharmaceutical companies.


EXPERT OPINION
Several novel therapeutic applications have been proposed for 5-HT1AR ligands, i.e. prostate cancer treatment, gastrointestinal and cardiopulmonary disorders, facilitation of urination and defecation, and L-DOPA-induced dyskinesia. Interestingly, no patent application has been filed by big pharma companies, while numerous researches are being conducted in smaller companies and academia.
['Staroń|Jakub|J|', 'Bugno|Ryszard|R|', 'Hogendorf|Adam S|AS|', 'Bojarski|Andrzej J|AJ|']
D000818:Animals D015195:Drug Design D006801:Humans D008024:Ligands D010330:Patents as Topic D044282:Receptor, Serotonin, 5-HT1A D058825:Serotonin 5-HT1 Receptor Agonists D058829:Serotonin 5-HT1 Receptor Antagonists
5-HT1A serotonin receptor agonist antagonist serotonin modulator therapeutic patent